Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care.

Walker CP, Hurlock NP, Deb S

Open source

DOI
10.3390/diseases12050107
Published
2024 May 20
Container
Diseases (Basel, Switzerland)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/diseases12050107,
  title = {Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care.},
  author = {Walker CP and Hurlock NP and Deb S},
  year = {2024},
  journal = {Diseases (Basel, Switzerland)},
  doi = {10.3390/diseases12050107},
  url = {https://doi.org/10.3390/diseases12050107}
}

RIS

TY  - JOUR
TI  - Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care.
AU  - Walker CP
AU  - Hurlock NP
AU  - Deb S
PY  - 2024
JO  - Diseases (Basel, Switzerland)
DO  - 10.3390/diseases12050107
UR  - https://doi.org/10.3390/diseases12050107
ER  - 

APA

CP, W., NP, H., & S, D. (2024). Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care.. Diseases (Basel, Switzerland). https://doi.org/10.3390/diseases12050107

Source records